Metal Ions in Life Sciences
Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
View Protocol Complete dosage protocol and reconstitution guide for GHRP-2 (10 mg Vial)
In aged mice treated for 8 weeks at 10 mg/kg daily, sedentary mice showed approximately 40% greater grip strength than controls, and when combined with exercise, grip strength improved by approximately 60%
This is the single most important dietary target for body composition during this stack
